The ABCs of ADCs: Why antibody-drug conjugates are so hot right now

FromBioSpace

Start listening View podcast show

The ABCs of ADCs: Why antibody-drug conjugates are so hot right now

FromBioSpace

ratings:

Length:

11 minutes

Released:

Mar 6, 2024

Format:

Podcast episode

Description

These days you can hardly move without figuratively bumping into antibody-drug conjugates (ADCs). This week we discuss Pfizer's strategic priorities for oncology - focused on ADCs and less on small molecules - and how the market is being influenced by the IRA.

Released:

Mar 6, 2024

Format:

Podcast episode

Titles in the series (47)

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Skip carousel

Q3 earnings recap: winners, losers & surprises by BioSpace
18 min listen
Zepbound vs Wegovy: a two horse race by BioSpace
14 min listen
Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure by BioSpace
18 min listen
Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA by BioSpace
21 min listen
Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety by BioSpace
17 min listen
Deals, Dupixent and GLP-1 drug shortages by BioSpace
17 min listen
The top life sciences startups to watch this year by BioSpace
15 min listen
Fast and furious evolution: how to ensure AI is catalyst for positive societal change with Microsoft and IQVIA by BioSpace
32 min listen
First ever CRISPR gene therapy approval: What happens next? by BioSpace
13 min listen
GLP-1 and ADC rollercoasters pick up speed by BioSpace
13 min listen
Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior by BioSpace
17 min listen
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital by BioSpace
45 min listen
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny by BioSpace
17 min listen
On the ground at #JPM2024 - Day 3 highlights by BioSpace
12 min listen
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics by BioSpace
48 min listen
What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital by BioSpace
22 min listen
Optimistic, but for how long? Our big takeaways from #JPM2024 by BioSpace
14 min listen
Grab an umbrella, it's raining ⁠IPOs⁠! by BioSpace
11 min listen
On the ground at #JPM2024 - Day 2 highlights by BioSpace
12 min listen
Every move you make: biopharma industry under heavy scrutiny by BioSpace
16 min listen
On the ground at #JPM2024 - Day 1 highlights by BioSpace
10 min listen
Iovance wins with Amtagvi and the ADC train chugs on by BioSpace
14 min listen
What can biopharma expect from the job market? by BioSpace
18 min listen
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo by BioSpace
12 min listen
Keep calm and CAR-T on? by BioSpace
18 min listen
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars by BioSpace
14 min listen
The gap is where the pain is: Drug pricing and patient costs by BioSpace
20 min listen
Historic approval for MASH, CAR-Ts in the spotlight by BioSpace
18 min listen
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now by BioSpace
11 min listen
Eyes on the prize: Novo buys Catalent by BioSpace
29 min listen

More Episodes from BioSpace

Skip carousel

Bayer’s New Strategy, Novo Vs. Lilly and Psychedelics by BioSpace
14 min listen
Bayer Layoffs, a Big Alzheimer’s Deal and ASGCT Wrap by BioSpace
15 min listen
Women's Health: Where Politics and Science Meet by BioSpace
22 min listen
ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird by BioSpace
12 min listen
BioSpace Heads to #ASGCT, Along with Thousands in Cell and Gene Therapy by BioSpace
12 min listen
The IRA, BMS’ Big Cuts, First WHIM Approval by BioSpace
16 min listen
Where Do We Go From Here? The Future of Women's Health by BioSpace
22 min listen
Sanofi Layoffs, CAR-T Warnings and a New GLP-1 Player by BioSpace
18 min listen
Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages by BioSpace
20 min listen
It's a Design Problem: Women and Clinical Trials by BioSpace
20 min listen
Alphabet Soup: AACR and ACC Dominate Headlines This Week by BioSpace
17 min listen
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo by BioSpace
12 min listen
Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients? by BioSpace
22 min listen
Bayer’s sweeping executive cuts, Wegovy’s expanding reach by BioSpace
17 min listen
Money talk: Salary trends and raises by BioSpace
15 min listen
Historic approval for MASH, CAR-Ts in the spotlight by BioSpace
18 min listen
The unintended consequences of small molecules by BioSpace
25 min listen
The skinny on weight loss, donanemab and the State of the Union by BioSpace
16 min listen
The gap is where the pain is: Drug pricing and patient costs by BioSpace
20 min listen
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars by BioSpace
14 min listen
Iovance wins with Amtagvi and the ADC train chugs on by BioSpace
14 min listen
Eyes on the prize: Novo buys Catalent by BioSpace
29 min listen
Balancing act: Patient access and innovation by BioSpace
21 min listen
Keep calm and CAR-T on? by BioSpace
18 min listen
What can biopharma expect from the job market? by BioSpace
18 min listen
Grab an umbrella, it's raining ⁠IPOs⁠! by BioSpace
11 min listen
Optimistic, but for how long? Our big takeaways from #JPM2024 by BioSpace
14 min listen
On the ground at #JPM2024 - Day 2 highlights by BioSpace
12 min listen
On the ground at #JPM2024 - Day 3 highlights by BioSpace
12 min listen
On the ground at #JPM2024 - Day 1 highlights by BioSpace
10 min listen

Related podcast episodes

Skip carousel

InvestTalk 11-27-2023 – Advantages and Disadvantages of Infinite Banking by InvestTalk
47 min listen
6/2/23: New Hope in the Fight Against Alzheimer’s by THE TRUTH ABOUT YOUR FUTURE with Ric Edelman
24 min listen
Expanding drug dosage possibilities…: In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Megan Greth, Director of Marketing & Business Development and Tadgh Prendeville, General Manager at ARx LLC. Your host, Raman Sehgal,... by Molecule to Market: Inside the outsourcing space
45 min listen
Stacy Havener - The Scientist and the Storyteller Miniseries (Pt. 1): This week on Standard Deviations with Dr. Daniel Crosby, Dr. Crosby is joined by Stacy Havener, of Billion Dollar Backstory, for the first part in an ongoing miniseries between the two podcasts. Stacy Havener has a made a career raising $8B+ for new/undiscovered funds that led to $30B+ in follow-on AUM. Prior to finding her niche in raising capital, she was an award-winning writer who dreamed of becoming a literature professor. Ironically, her love of words is one of the secrets to her success in an industry dominated by numbers. Growing up the only girl on all-boy soccer teams, it’s no surprise she’s now a female entrepreneur in one of the toughest “boys clubs.” At the heart of it all, there is one thing Stacy believes in – underdogs. Stacy is the Founder/CEO at Havener Capital Partners, a sales and marketing agency that helps boutique asset managers build, launch and grow funds. Havener Capital is on a mission to l by Standard Deviations with Dr. Daniel Crosby
43 min listen
Addressing strategic challenges for biotech companies by Conversations in Healthcare
31 min listen
Medical AI interview W/ David Canes by The ChatGPT Report
20 min listen
Episode 136 — Private Equity’s Impact: Dynamics, Risks, and Strategies by The Boardroom Buzz Pest Control Podcast
51 min listen
Ambulatory Surgery Centers – Taking Surgery Out Of The Operating Room With Ryan Aldridge: Ambulatory surgery centers represent a future for healthcare where people can have the option to have their elective surgical procedures done outside of the hospital. A few market disruptors have been developing this business model for many years, but... by The Medical Sales Podcast
48 min listen
Early planning key to successful access and product launch by Conversations in Healthcare
30 min listen
Balance patient focus with commercial objectives by MSL Consultant Podcast
23 min listen
EP #161 | Our appetite to Risk while seeking financial freedom | + News about CVS and our thoughts on Medical Properties Trust by Dividend Talk
65 min listen
Understanding the Connection Between Complaints, CAPAs, and MDRs: Today we are going to talk about the connection between complaints, CAPAs, and MDRs. They are all interrelated and they have a big part of developing your company’s culture and affecting your risk management processes. Mike Drues, president of Vascula... by Global Medical Device Podcast powered by Greenlight Guru
37 min listen
What Are Antibodies, and Why Are We Testing for Them? by BrainStuff
7 min listen
The DOAC Reversal Controversy ft Dr. Brian Gilbert: On this episode, we are joined by Brian Gilbert, PharmD, BCPS, BCCCP, David Moran, PharmD, and Jacob Reeder, PharmD, BCCCP to discuss andexanet alfa (Andexxa). We contrast the DOAC benefits that are popular among the ambulatory care community with the... by CorConsult Rx: Evidence-Based Medicine and Pharmacy
52 min listen
Transforming the treatment of cancer with oncolytic viruses by Conversations in Healthcare
33 min listen
Significant Risk vs. Nonsignificant Risk Devices - What's the Difference?: Do you understand the difference between significant risk and nonsignificant risk when it comes to the development and design of your medical devices? It’s important to classify devices properly, and the difference between SR and NSR is not always wel... by Global Medical Device Podcast powered by Greenlight Guru
34 min listen
The Third Biologic Revolution with Vaxxinity CEO Mei Mei Hu by The 7investing Podcast
31 min listen
248 StrategyMan vs the Anti-Strategy Squad by Rich Horwath: StrategyMan vs. the Anti-Strategy Squad: Using Strategic Thinking to Defeat Bad Strategy and Save Your Plan by Rich Horwath MEDAL WINNER: AXIOM BUSINESS BOOK AWARDS From the New York Times bestselling author on strategy All over the world,... by The Marketing Book Podcast
64 min listen
Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D. by The Chain: Protein Engineering Podcast
33 min listen
De-Risking Your Portfolio Without Giving Up On Strong Returns: J.D. Gardner started ETF firm Aptus to attack what he terms the "behavior gap" in investing, whereby investors routinely underperform their underlying investments by "performance chasing". Aptus' flagship fund, DRSK, attacks the behavior gap frontally... by Let's Talk ETFs
53 min listen
AI in Insurance - Addressing Compliance Considerations - with Pardeep Bassi of WTW: In this episode, we’re focusing on compliance considerations in the insurance world. Our guest this week is Pardeep Bassi. He is currently Global Proposition Leader of Data Science for WTW, or Willis Towers Watson, a publicly traded financial... by The AI in Business Podcast
31 min listen
Questions About Breast Implants and More: Since the FDA's recent warnings, there have been many more questions regarding breast implants. Dr. Rady answers his listener's questions, everything from; can mammograms detect cancers associated with breast implants too, can capsular contracture be... by Plastic Surgery Uncensored
34 min listen
Special Encore: Mark Purcell: The Evolution of Cancer Medicines by Thoughts on the Market
4 min listen
The Promising Field of Targeted Protein Degraders (TPDs): Dr. Mavra Nasir recently published a thought piece in Biopharma Dealmakers outlining the current state of play in the promising field of protein degradation. In this episode, Dr. Nasir sits down with Peter Bak to discuss the recent surge of venture fundin by Back Bay Life Science Report
23 min listen
How To Survive the Coronavirus (Covid-19) Shutdown by Money For the Rest of Us
25 min listen
Rethinking Cancer - How a Shift in Thinking Can Lead To Revolutionary Understanding with Richard Jacobs and Perry Marshall: Is how we think about and approach cancer all wrong? By reexamining the roots of cancer evolution, a shift in thinking may lead to significant new developments. Listen up to learn: How Richard Jacobs became invested in researching cancer and the... by Finding Genius Podcast
53 min listen
118: Commercial risk is possible—here's how: Host Rachel Woods sits down with Advisory Board's Clare Wirth and Alex Taillian to discuss their research into commercial risk and why they believe commercial risk is possible for the health care industry. by Radio Advisory
20 min listen
The CRO scientist turned entrepreneur: In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Richard Weaver, Founder and Managing Director at Drug Discovery Solutions. Your host, Raman Sehgal, discusses the pharmaceutical ... by Molecule to Market: Inside the outsourcing space
44 min listen
The Math Behind Mill | EDHRECast 120: How viable is the Mill strategy in EDH? What are its biggest hurdles and greatest strengths? Today the guys dive into the intricate numbers surrounding the Mill archetype. How many turns does it take to mill someone out? How many Petitioners does it... by EDHRECast
53 min listen
How Similar Is the Opioid Epidemic to the Crack Epidemic?: The War on Drugs being waged against opioids is very different than the one that was fought against crack. Learn more about the politics of race and addiction in this episode of BrainStuff. by BrainStuff
6 min listen

Discover this podcast and so much more

The ABCs of ADCs: Why antibody-drug conjugates are so hot right now

The ABCs of ADCs: Why antibody-drug conjugates are so hot right now

Description

Titles in the series (47)

More Episodes from BioSpace

Related podcast episodes